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Abstract 
In this work, tigapotide (PCK3145) was incorporated into novel nanocarriers based on 
polymeric, lipidic and dendrimeric components, in order to maximize the advantages 
of the drug delivery process and possibly its biological properties. PCK3145 was 
incorporated into lipidic nanocarriers composed of Eggphosphatidylcholine (EggPC) 
and dipalmytoylphosphatidylcholine (DPPC) (EggPC:PCK3145 and 
DPPC:PCK3145, 9:0.2 molar ratio), into cationic liposomes composed of  
EggPC:SA:PCK3145 and DPPC:SA:PCK3145 (9:1:0.2 molar ratio) into complexes 
with the block polyelectrolyte  (quaternized poly[3,5-
bis(dimethylaminomethylene)hydroxystyrene]-b-poly(ethylene oxide) (QNPHOSEO) 
and finally into dendrimeric structures (i.e. PAMAM G4) . Light scattering techniques 
are used in order to examine the size, the size distribution and the z-potential of the 
nanocarriers in aqueous and biological media. Fluorescence spectroscopy was utilized 
in an attempt to extract information on the internal nanostructure and 
microenvironment of polyelectrolyte/PCK3145 aggregates. Therefore, these studies 
could be a rational roadmap for producing various effective nanocarriers in order to 
ameliorate the pharmacokinetic behavior and safety issues of antitumor and anticancer 
biomolecules.  
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Introduction 
 
Drug delivery has matured from its original goal of prolonging the duration of drug 
release; it now involves customized systems that are designed to achieve specific 
spatial and temporal control; future generations of drug-delivery systems will 
incorporate “smart” biosensing functionalities that will enable unaided in vivo 
feedback control (Kaditi et al., 2012; Crommelin and Florence, 2013). The properties 
of an ideal drug delivery or biomedical vector are the structural control over size and 
shape of drug or imaging-agent cargo-space, biocompatibility, nontoxic 
polymer/pendant functionality, the lack of immunogenicity and the precise, 
nanoscale-container and/or scaffolding properties with high drug or imaging-agent 
capacity features (Rowland et al., 2012; Crommelin and Florence, 2013). From a 
pharmacokinetic point of view, ideal drug delivery systems have a well-defined 
scaffolding and/or surface modifiable functionality for cell specific targeting moieties 
(Crommelin and Florence, 2013). 
Liposomes are widely used for entrapment of therapeutic agents, and were developed 
to increase antitumor efficacy of a wide variety of drug molecule and biomaterials 
such as peptides and oligonucleotides (Bangham et al., 1965; Gregoriadis et al., 1974; 
Hofheinz et al., 2005; Slingerland et al., 2012). In two past decades, cationic 
liposomes have been used extensively for gene delivery (Ruozi et al., 2003). The 
positive charge on the liposomal surface plays a crucial role because it allows the 
establishment of strong electrostatic interactions between the liposomal bilayer and 
the negatively bioactive compounds (Wu and McMillan, 2009; Kapoor et al., 2012). 
Additionally, the interactions of cationic liposomes with cell membrane models and 
plasma proteins have been already studied (Bonicelli et al., 2011; Capriotti et al., 
2012; Pippa et al., 2012a). 
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Furthermore, asymmetric amphiphilic block copolymers self-assemble in aqueous 
media, to form a core-shell micellar structures and morphologies, with a mesoscopic 
or nanoscopic narrow size range and are used for biomedical and pharmaceutical 
applications (in the order of 10-100 nanometers) (Torchilin, 2004, 2009). 
Polyelectrolyte block copolymers constitute an intriguing class of bio-inspired 
macromolecules, as they combine the structural properties of amphiphilic block 
copolymers, polyelectrolytes and surfactants and provide various possibilities for use 
as delivery nanosystems of genes and proteins through electrostatic complexation (Al-
Tahami and Singh, 2007; Hartig et al., 2007; Pispas, 2007; Reis et al., 2008; 
Karayianni et al., 2011; Karayianni and Pispas, 2012; Becker et al., 2012; Haladjova 
et al., 2012; Varkouhi et al., 2012).  
Additionally, dendrimers are characterized as the 4th architectural class of polymers 
and represent a new category of drug delivery nanosystems. Due to their precise 
architecture, dendrimers possess an advantage over other generally polydisperse 
nanoparticles and this allows for greater control over their pharmacodynamic profile, 
while as vehicles for drug delivery they can be used either for encapsulation of 
bioactive compounds or for their covalent or non-covalent attachment at the periphery 
(Esfand and Tomalia, 2001; DeMattei et al., 2004; Demetzos, 2006; Chauhan et al., 
2009; Tomalia et al., 2007, 2009; Menjoge et al., 2010). Cheng et al. (2008) pointed 
out that dendrimers have successfully proved themselves as useful additives in 
different routes of drug administration (intravenous, oral, transdermal, and ocular 
delivery systems) because they can render greater water-solubility and bioavailability 
to drugs. An ideal dendrimer, which is a highly branched macromolecule, must be 
non-toxic, non-immunogenic and biodegradable in order to be considered as a 
nanostructured drug delivery system (Cloninger, 2002; Aulenta et al., 2003). The first 
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complete dendrimer family which has been synthesized, characterized and 
commercialized is the Poly(amidoamine) (PAMAM) dendrimers. They are 
characterized as safe and non-immunogenic and they are used in drug delivery, 
delivery of antisense nucleotides and gene therapy, both in vitro and in vivo due to the 
reproducibility of their pharmacokinetic behavior (Eichman et al., 2001; Asthana et 
al., 2005; Svenson and Tomalia, 2005). According to the literature, dendrimers have 
been shown to cross cell barriers and membranes by the mechanism of endocytosis 
(Jevprasesphant et al., 2004; Sadekar and Ghandehari, 2012). 
Modulatory Controlled Release profile (MCR) denoted as Modulatory Controlled 
Release nano Systems (MCRnSs) are considered as drug delivery systems that can 
modulate the release of the encapsulated bioactive compound (Gardikis et al., 2010, 
2011; Pippa et al., 2013a,b,c,d). The nature of the elements used for producing 
advanced biomaterials are of great importance and medicinal chemistry and new 
synthetic bioelements (i.e. new polymeric and dendritic structures) play a crucial role 
in their production (Tomalia, 2009).  
It has been reported that a synthetic 15-mer peptide, tigapotide (PCK3145), derived 
from prostate secretory protein, can reduce tumor growth, experimental skeletal 
metastases, and melignacy associated hypocalcaemia (Shukeir et al., 2004; Annabi et 
al., 2005, 2006). Additionally, it has being shown that the incorporation of bioactive 
compounds with antitumor effects into nanocarriers modified their cellular uptake by 
favoring the selective accumulation in cell membranes from where they had 
demonstrated prolonged release (Crommelin and Florence, 2013). 
The goal of this study is to design and develop effective nanocarriers for tigapotide 
based on polymeric, lipidic and dendritic components. Prime interest is focused on the 
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determination of the physicochemical (i.e. size, ζ-potential, Polydispersity Index 
(PD.I.), and morphology) of the produced nanoparticles. We employ dynamic (DLS), 
static (SLS) and electrophoretic (ELS) light scattering in order to examine the 
complexation process, as well the structure and solution behavior of the nanosized 
complexes in aqueous and biological media, formed between quaternized poly[3,5-
bis(dimethylaminomethylene)hydroxystyrene]-b-poly(ethylene oxide) (QNPHOSEO), 
a cationic-neutral block copolymer, and PCK3145. The physicochemical 
characteristics and stability studies of different liposomal formulations 
(DPPC:PCK3145 and EggPC:PCK3145 (9:0.2 molar ratio) and DPPC:SA:PCK3145 
and EggPC:SA: PCK3145 (9:1:0.2 molar ratio) incorporating tigapotide are also 
presented in this work. The purpose of this study also includes the examination of the 
complexation process of PAMAM-G4 dendrimer with PCK3145.  
Experimental  
 
Materials 
 
The phospholipids used for liposomal formulations were Egg phosphatidylcholine 
(EggPC) and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC). They were 
purchased from Avanti Polar Lipids Inc., (Albaster, AL, USA) and used without 
further purification. Chloroform, Stearylamine (SA, Octadecylamine) and all other 
reagents used were of analytical grade and purchased from Sigma–Aldrich Chemical 
Co. PAMAM Dendrimer generation 4 (empirical formula C622H1248N250O124, formula 
weight: 14214.17) was purchased from Aldrich. The synthesis, the physicochemical 
characterization, as well as the properties of QNPHOSEO are presented extensively in 
the recent literature (Mountrichas et al., 2006; Mountrichas and Pispas, 2007; 
Mantzaridis et al., 2009; Stepanek et al., 2011). The QNPHOSEO polyelectrolyte 
block copolymer was characterized by SEC, 1H-NMR and FTIR and it was found to 
7 
 
have the following molecular characteristics: Mw=98,600, Mw/Mn=1.09, 15%wt PEO. 
The Tigapotide (PCK3145) is manufactured at PolyPeptide Laboratories (formerly 
Neo MPS) via solid phase synthesis incorporating Fmoc (9-
Fluorenylmethyloxycarbonyl) protective groups. An acetylaminomethyl group is 
attached to the sulphur at each of the three cysteines within the peptide. The peptide is 
synthesized as the trifluoroacetate (TFA) salt. The amino acid sequence is as follows: 
H2N-Glu-Trp-Gln-Thr-Asp-Asn-Cys (AcM)-Glu-Thr- Cys (AcM)-Thr-Cys (AcM)-
Tyr-Glu-Thr-OH and the chemical formula is C82H121N21O34S3 (molecular weight: 
2039.14).  The structures of QNPHOSEO, PAMAM G-4 and PCK3145 are presented 
in Fig. 1. The lipids’ chemical structures as well as the structure of dendrimer are  is 
widely known.  
Preparation of QNPHOSEO:PCK3145 polyelectrolyte aggregates in different aqueous 
media  
A pH 7 buffer solution was prepared from NaOH and 5mM sodium phosphate, 
Moreover, 10mM NaCl were added to solution to maintain a fixed ionic strength, 
along with NaN3 in a final concentration of 200ppm, in order to avoid bacterial 
growth. Stock solutions of PCK3145 and of QNPHOSEO were prepared by 
dissolving a weight amount of the dialyzed sample in the appropriate volume of the 
buffer and the solutions were left to stand overnight for better equilibration. 
The complexes were prepared by adding different amounts of the PCK3145 solutions 
to QNPHOSEO solutions of the same volume and concentration, under stirring. 
Finally, appropriate volumes of buffer solutions were added to achieve a constant 
final volume and ionic strength (equal to that of the buffer solutions) for all solutions 
prepared. Thus, the concentration of QNPHOSEO was kept constant throughout the 
series of solutions, while that of PCK3145 varied in order to control the required ratio 
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of the two components (or equivalently the [-]/[+] charge ratio of the mixture). The 
solutions of the complexes developed a bluish tint or turbidity upon mixing, 
indicating the formation of supramolecular complexes. Subsequently, the solutions of 
the complexes were left for equilibration overnight, which in some cases resulted in 
coacervation, i.e. liquid-liquid phase separation of the solution, depending on the 
PCK3145 concentration and pH. Stable solutions were further characterized as 
discussed below. 
For the ionic strength dependent light scattering measurements, the ionic strength of 
the solution was gradually increased by the addition of appropriate aliquots of 1N 
NaCl solution at pH=7.00 or 7.40, to 1ml of the previously prepared solutions of the 
complexes. After each addition the solution was rigorously stirred and left to 
equilibrate for 15min before measurement. Changes in solute concentrations due to 
NaCl solution addition were taken into consideration in the analysis of the light 
scattering data.    
Preparation of liposomal nanocarriers 
 
Different liposomal formulations have been prepared using the thin-film hydration 
method. Briefly, appropriate amounts of DPPC or EggPC and/or EggPC:SA or 
DPPC:SA mixtures were dissolved in chloroform/methanol (9:1 v/v) and then 
transferred into a round flask connected to a rotary evaporator (Rotavapor R-114, 
Buchi, Switzerland). Vacuum was applied and the phospholipids thin film was formed 
by slow removal of the solvent at 50°C. The mixed film was maintained under 
vacuum for at least 24h in a desiccator in order to remove traces of solvent and 
subsequently it was hydrated in solution of PCK3145 in Phosphate Buffer Saline 
(PBS), by slowly stirring for 1h in a water bath above the phase transition temperature 
of lipids (41°C for DPPC and 23°C for EggPC). The resultant nanostructures 
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(apparently multilamellar vesicles, MLVs) were subjected to two, 3min and 2min 
sonication cycles (amplitude 70, cycle 0.7) interrupted by a 3min resting period, in a 
water bath, using a probe sonicator (UP 200S, dr. Hielsher GmbH, Berlin, Germany). 
The resultant liposomes (tentatively assigned as small unilamellar vesicles, SUVs) 
were allowed to anneal for 30min. The effect of PCK3145 incorporation in liposomal 
preparations was evaluated by measuring the size distribution and ζ-potential of the 
nanocarriers. The mean hydrodynamic diameter was used for the characterization of 
the liposomal dispersion immediately after preparation (t = 0 day), as well as for the 
monitoring of their physical stability over time.  
Preparation of dendritic nanocarriers 
 
The complexes were prepared by adding different amounts of the PCK3145 solutions 
to PAMAM-G4 solutions and by adding different amounts of the PAMAM-G4 
solutions to PCK3145 solutions in different molar ratios, under stirring. Finally, 
appropriate volumes of buffer solutions were added to achieve a constant final volume 
and ionic strength (equal to that of the PBS) for all solutions prepared. 
Techniques 
Dynamic and static light scattering 
The hydrodynamic radius (Rh) of nanocarriers and the polydispersity index (PD.I.) 
were measured by dynamic light scattering (DLS) and the ratio of  radius of gyration 
to hydrodynamic radius (Rg/Rh) was determined by static light scattering (SLS). Mean 
values and standard deviations were calculated from three independent samples. For 
dynamic and static light scattering measurements, an AVL/CGS-3 Compact 
Goniometer System (ALV GmbH, Germany) was used, equipped with a cylindrical 
JDS Uniphase 22mV He-Ne laser, operating at 632.8 nm, and an Avalanche 
photodiode detector. The system was interfaced with an ALV/LSE-5003 electronics 
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unit, for stepper motor drive and limit switch control, and an ALV-5000/EPP multi-
tau digital correlator.  Autocorrelation functions were analyzed by the cumulants 
method and the CONTIN software. Apparent hydrodynamic radii, Rh, at finite 
concentrations, were calculated by aid of the Stokes - Einstein equation: 
 
where kB is the Boltzmann constant, η0 is the viscosity of water at temperature T, and 
D is the diffusion coefficient at a fixed concentration. The polydispersity of the 
particle sizes was given as the  (PD.I.) from the cumulants method, where Γ is 
the average relaxation rate, and μ2 is its second moment. 
Light scattering has been used widely in the study of the fractal dimensions of 
aggregates. In static light scattering, a beam of light is directed into a sample and the 
scattered intensity is measured as a function of the magnitude of the scattering vector 
q, with:  
 
where n0 is the refractive index of the dispersion medium, θ is the scattering angle and 
λ0 is the wavelength of the incident light. Measurements were made at the angular 
range of 30º to 150º (i.e. the range of the wave vector was 0.01<q<0.03 cm-1).  
The general relation for the angular dependence of the scattered intensity, I(q) is: 
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where df is the fractal dimension of the liposomes or aggregates with 1≤df ≤3 (df=3 
corresponds to the limit of a completely compact Euclidean sphere where less 
compact structures are characterized by lower df values). The above equation is the 
classical result used to determine the mass fractal dimension from the negative slope 
of the linear region of a log-log plot of I vs. q.  
Electrophoretic mobility – microelectrophoresis 
The zeta potential (ζ-potential) plays an important role in colloidal stability of 
nanoparticles and can be readily measured by the technique of microelectrophoresis 
(Delgado et al., 2007). The zeta potential of chimeric nanostructures was measured 
using Zetasizer 3000HAS, Malvern Instruments, Malvern, UK. 50μl of the 
dispersions was 30-fold diluted in dispersion medium and ζ-potential was measured at 
room temperature at 633nm. The zeta potentials were calculated from electrophoretic 
mobilities, μΕ, by using the Henry correction of the Smoluchowski equation: 
 
where is the permittivity of the vacuum,  is the relative permittivity, α is the 
particle radius, κ is the Debye length, and n is the viscosity of water. The function 
f(κα) depends on particle shape. While if κα > 1: 
 
The above function refers to dispersions of the present study.  
Fluorescence Spectroscopy 
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Steady-state fluorescence spectra of pyrene probe in the solutions of nanostructures 
were recorded with a double-grating excitation and a single-grating emission 
spectrofluorometer (Fluorolog-3, model FL3-21, Jobin Yvon-Spex) at room 
temperature (25ºC). Excitation wavelength was λ=335 nm  for pyrene and emission 
spectra were recorded in the region 350–600 nm, with an increment of 1 nm, using an 
integration time of 0.5 s. Slit openings of 1 nm were used for both the excitation and 
the emitted beams. The dispersions containing the probe were left to equilibrate in the 
dark at 4°C for 24h before the measurements. The intensity ratio of peak 1 to peak 3, 
I1/I3, serves as a measure of the micropolarity, i.e. larger I1/I3 ratio designates higher 
polarity of the surrounding medium. The microfluidity was estimated from the 
fluorescence intensity ratio IE/IM, where IE and IM are the fluorescence intensities of 
pyrene excimer and monomer, respectively. IE and IM were measured at emission 
wavelengths 480 and 372nm, respectively. The fluorescence intensity ratio IE/IM 
offers an index of microfluidity, because the ratio IE/IM is proportional to the 
frequency of collisions of pyrene molecules, namely the ability to form excimer. 
Typically, larger values of IE/IM imply a larger microfluidity.  
Results and Discussion 
 
Physicochemical characterization of QNPHOSEO:PCK3145 complexes. 
The complexation process between the QNPHOSEO polyelectrolyte and PCK3145 at 
pH=7.00 and at pH=7.40 was first investigated by means of dynamic light scattering.  
It should be noted that PBS (pH=7.40) was chosen as dispersion medium because the 
pH and the ionic strength of PBS resembles the conditions met within the human 
body. At pH=7.00 the electrostatic interactions of the system are expected to be 
strong, since the QNPHOSEO polyelectrolyte block carries two positively charged 
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groups per functionalized monomeric unit and PCK3145 has a net negative charge of 
-4. The obtained results from DLS measurements at 90° regarding the values of the 
light scattering intensity, I90 (corrected for the concentration increase) and 
hydrodynamic radius, Rh, are shown in Figures 2(a) and (d), as function of the peptide 
concentration, CPCK3145, in the solutions of the complexes. The concentration of 
QNPHOSEO copolymer is kept constant throughout the series of aqueous solutions of 
different ionic strength investigated. DLS results at low ionic strength (0.01M) show 
that all solutions exhibit a main peak at high Rh values (~40nm), which apparently 
corresponds to the formed mixed aggregates and a significantly smaller one at lower 
Rh values, which most probably denotes the presence of a small number of free 
unimer diblock copolymer chains in solution. The values of the scattering intensity, 
I90, which is proportional to the mass of the species in solution, increased gradually as 
a function of CPCK3145, providing proof of the occurring complexation (Fig.2(d)), i.e. 
the mass of the complexes increases as CPCK3145 increases. As peptide concentration 
increases each polyelectrolyte chain interacts with an increasing number of peptide 
molecules, the degree of charge neutralization becomes higher and the size 
distribution of the complexes decreases, especially in the lowest ionic strength 
(Becker et al., 2012). In contrast I90 (and mass of the complexes) remains almost 
constant in the case of PBS solutions. ζ- potential decreases in absolute value as the 
concentration of the peptide increases, or equivalently the effective positive charge of 
the complexes reduces as a function of the peptide concentration. The values of Rg/Rh 
were also calculated (Fig 2.(e)).  This ratio is sensitive to the shape of particles in 
solution and can be used as a rough estimate of the internal morphology of the 
particle. This is based on the notion that Rg is a measure of the mass density 
distribution around the center of the structure, while Rh defines the outer dimensions 
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of the particle. According to Burchard (1983), the ratio Rg/Rh takes the values of 0.775 
for a hard uniform sphere and 1.0 for vesicles with thin walls, while values of 1.3 to 
1.5 indicate a random coil (loose) conformation in the case of macromolecular chains. 
In the present case, the values Rg/Rh
 are near 1.00 for QNPHOSEO:PCK3145  at PBS, 
and these observations may indicate a more well-defined hollow sphere (vesicle like) 
structure for the aggregates (Fig 2.(e)) or a rather low density full spherical structure. 
On the other hand, the values Rg/Rh indicate open (low density) spherical structures 
for aggregates in the pH=7.00 buffer (Fig 2.(e)). These differences may be a result of 
the differences in the salinity of the media. 
It is important to characterize the physicochemical properties of the nanostructures in 
biological media, like FBS, because interaction with proteins of the medium is 
expected to alter the physicochemical properties of the nanostructures, thereby 
affecting their stability and clearance properties (Arnida, Janát-Amsbury et al., 2011). 
The size of complexes in biological medium (FBS) was not increased significantly 
(Figure 3). This observation indicates that QNPHOSEO copolymer imparts stealth 
properties and stability in the complexes, due to the presence of PEO chains that 
shield the complexes. A shift of ζ-potential to negative values is observed presumably 
due to some binding of FBS proteins, which can alter the nanoparticle’s effective size 
and surface properties (the main protein component of FBS is albumin which carries a 
negative charge at physiological conditions) (Law et al., 1986; Sabín et al., 2009; 
Pippa et al., 2012a,b). 
Effect of ionic strength 
The increase of the ionic strength in the solutions of the complexes induces charge 
screening and weakening of the electrostatic interactions, so it is expected to greatly 
influence the solution behavior and structure/morphology of the performed 
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complexes. In order to investigate this effect, DLS/SLS measurements as a function of 
the added NaCl concentration were conducted, and the resulting I90 (corrected for the 
difference in concentration) and Rh values for representative solutions at low and high 
CPCK3145 values of QNPHOSEO:PCK3145 system at pH 7.00 and 7.40 are shown in 
Figs. 4. and 5. The hydrodynamic radius of the complexes, as a function of PCK3145 
concentration, remained more or less unaffected in the case of PBS buffer (Fig. 5(a)), 
while their morphology changed and more compact structures are observed (Fig. 5(c)) 
(Karayianni and Pispas, 2012). 
At pH 7.00 the solutions of the complexes exhibit a different response to the increase 
of the ionic strength, apparently due to the particular structure of the formed 
complexes in each solution (Fig. 4.) We recall that at low CPCK3145 values the number 
of interacting peptide molecules per polyelectrolyte chain is rather small, while at 
high CPCK3145 values the formed complexes are characterized by rather large number 
of interacting peptide molecules per polyelectrolyte chain (Karayianni et al., 2011). 
The aggregation of the complexes is marked by a subsequent gradual increase of their 
size (Fig. 4a). Respectively, an abrupt increase of the mass of the complexes is 
observed at higher CPCK3145 upon addition of the salt at both pHs (Figs. 4b and 5b). It 
seems that in this case the increase of the ionic strength results to a secondary 
aggregation, because the number of QNPHOSEO chains in respect to PCK3145 is 
small. 
In general, it was determined that the increase of the ionic strength in the solutions of 
the complexes eventually causes the aggregation of the preformed complexes. This 
effect arises from the induced charge screening that weakens the electrostatic 
interactions of the systems. Of course, one should keep in mind that the weakening of 
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the electrostatic interactions enhances the role of the existing hydrophobic interactions 
in the system (QNPHOSEO has a hydrophobic backbone and side groups). 
Fluorescence spectroscopy has been utilized in an attempt to extract information on 
the internal structure and microenvironment of nanostructures in aqueous solutions. 
The ratio I1/I3 in the fluorescence emission spectrum of pyrene is used as a measure of 
the polarity of the environment of the pyrene probe. In aqueous or similarly polar 
environment this ratio is found between 1.6 and 1.9. High values of the Ι1/Ι3 ratio were 
observed for the complexes (Table 1), which interestingly remained unaffected as the 
PCK3145 concentration increased. The behavior should be related to the significantly 
hydrophilic nature of the QNPHOSEO copolymer and that of the complexes 
(Mountrichas et al., 2006; Mountrichas and Pispas, 2007; Mantzaridis et al., 2009; 
Stepanek et al., 2011). 
The physicochemical characteristics of liposomal and dendritic nanoparticles 
incorporating tigapotide.   
Physicochemical characteristics of different liposomal formulations in PBS are 
presented in Table 2. The incorporation of PCK3145 leads to increased size of 
liposomes, especially for the nanocarriers incorporating SA (Table 3). The decrease of 
ζ-potential values indicates that there is an electrostatic attraction between the positive 
charge of liposomal membrane and the PCK3145.  In our opinion, this electrostatic 
attraction is the driving force for the peptide’s encapsulation attachment in the 
liposomal internal and external surface. For this reason, we observed a statistically 
significant increase of the size of liposomes DPPC:SA:PCK3145 (9:0.2:1 molar ratio) 
and EggPC:SA:PCK3145 (9:0.2:1 molar ratio), in comparison to neat liposomal 
nanocarriers (Table 2). Temporal colloidal stability of the initially formed chimeric 
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nanostructures in PBS was investigated (Fig. 6).  Generally, size and size distribution 
control is of a great importance in preparing liposomal formulations, because 
liposomal size can modulate the biological stability, the Adsorption, Distribution, 
Metabolism, Excretion and Toxicity (ADMET) profile of encapsulated bioactive 
compound, the biopharmaceutical/pharmacokinetic behavior and the capture 
mechanism by macrophages (Amado et al., 2009; Vallianatou and Tsantili-
Kakoulidou, 2013). The stability study over time for all liposomal formulations 
incorporating PCK3145 was performed by measuring the nanocarrier size and size 
distribution for a period up to two weeks. The liposomal suspensions were kept under 
dark at 4 ◦C. The two liposomal nanocarriers incorporating the tigapotide, without 
SA, in PBS were found to retain their original physicochemical characteristics for at 
least a week (Fig. 6). No sedimentation was observed, while their average size did not 
increase significantly, for DPPC:PCK3145(9:0.2 molar ratio) and EggPC:PCK3145 
(9:0.2 molar ratio), probably due to the existence of hydration forces (Ohki and 
Ohshima, 1999; Ohki and Alnord, 2000; Heutault et al., 2003). On the other hand, the 
size of DPPC:SA:PCK3145(9:1:0.2 molar ratio) and EggPC:SA:PCK3145 (9:1:0.2 
molar ratio) decreased significantly one day after the preparation of liposomal 
nanoparticles (Fig. 6) and remained unaffected up to a week. Then, an increase of the 
Rh of these liposomal formulations was observed. In our point of view this unexpected 
behavior was due to the release of PCK3145 from the DPPC:SA (9:0.2 molar ratio) 
and EggPC:PCK3145 (9:0.2 molar ratio) liposomal nanocarriers and their size 
reduced significantly. After, the release of tigapotide the liposomal nanocarriers 
aggregated due to the absence of electrostatic repulsion, as indicated from ζ-potential 
values (Table 2) (Heutault et al., 2003).  
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Furthermore, we examined the complexation process between tigapotide and 
PAMAM-G4 dendrimer in PBS by two different protocols via ζ-potential as they 
were presented previously. The core of PAMAM is a diamine (commonly 
ethylenediamine), which is reacted with methyl acrylate, and then another 
ethylenediamine to make the generation-0 (G-0) PAMAM by click chemistry. Low 
generation dendrimers can be thought of as flexible molecules with no appreciable 
inner regions, while medium sized dendrimers do have internal space that is 
essentially separated from the outer shell of the dendrimer (Tomalia et al., 1985). 
Dendrimers are utilized for their tertiary amine groups at the branching points within 
the dendrimer. Due to their relatively high pKa value (pKa 9.2), the primary amine 
groups undergo protonation at neutral pH so that there is a high density of positive 
charges on the surface of PAMAM dendrimers, which enables the formation of nano-
sized complexes with negatively charged peptides and proteins through electrostatic 
interactions (Choi et al., 2006; Ainalem et al., 2010; Jin et al., 2011). Due to their low 
pKa (pKa 6.7), tertiary amine groups in the PAMAM interior are protonated only at 
acidic pH environments (Jin et al., 2011). According to the recent literature, the 
binding mode of a bioactive compound to the dendrimer was found to be dependent 
not only on dendrimer’s physicochemical characteristics (i.e. size, pKa, nature of 
functional groups) and structure of the biomolecules, but also on dendrimer 
generation, core structure and surface charge of dendrimer (D’ Emanuele and 
Attwood, 2005; Gupta et al., 2006; Maingi et al., 2012). For the last reason, we chose 
ζ-potential in order to extract information on the complexation process of these 
biomaterials. The ζ-potential values of the PAMAM-G4:PCK complexes in PBS at 
different molar ratios and different preparation protocols are presented in Table 4.  
The ζ-potential of PAMAM-G4 dendrimers as well as of PCK3145 was found near 
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zero in PBS (Table 4). The ζ-potential was not changed significantly by the addition 
of PCK3145 solutions into PAMAM-G4 dendrimer solutions (Table 3A). On the 
other hand, the addition of PAMAM-G4 dendrimer solution into PCK3145 solution 
caused a shift from slightly negative to slightly positive values (Table 3B). It is 
supposed that the relatively low positive zeta-potential of mixed dendritic 
nanostructures comparing to free tigapotide is due to the imperfect complexation 
efficiency of peptide moiety on the surface of dendrimer as mentioned above, 
resulting to the loss of negative charge of the PCK3145 at neutral pH. In our opinion, 
these observations could be a first indication that the preparation protocol affects the 
complexation of the peptide into dendritic nanoparticles. The structure of dendritic 
nanoparticles incorporating tigapotide is presented in Scheme 1. Due to its relatively 
large size PCK peptide is difficult to be incorporated in the dendrimer’s interior. PCK 
is expected to interact with the surface amine groups and to be located close to the 
dendrimer surface.  
Conclusions  
This investigation relates to novel nanocarriers of tigapotide including polymer, lipid 
and dendrimer based nanoparticles and their use in the treatment of disease.  These 
nanocarrier compositions are expected to maximize the advantages of the peptide 
delivery process,  and consequently the biological properties (i.e. antitumoral) of 
tigapotide.  Dynamic (DLS), static (SLS) and electrophoretic (ELS) light scattering 
were used to examine the size, the size distribution, the z-potential, as well as the 
structural characteristics of the carriers in aqueous and biological media. The behavior 
of the nanosystems greatly depends on the nature of the components and their ratio. 
This study provides interesting and useful new insights into the interaction 
mechanism between oppositely charged block polyelectrolyte aggregates with stealth 
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properties and therapeutic peptides. The encapsulation of this antitumor peptide is 
higher into liposomes incorporating stearylamine, as indicated from the liposomal 
formulations’ physicochemical characteristics. To the best of the authors’ knowledge 
this is the first report on the encapsulation of tigapotide in different nanoparticulate 
carriers. The results of our study contribute to the overall scientific efforts to prepare 
efficient carriers for tigapotide and could be useful in order to develop nanocarriers 
with increased efficacy, safety and tolerability. The prepared nanocarriers can disclose 
the pharmacokinetic reality of behavior of tigapotide and improve its therapeutic 
value and side effects. This is because of the interdependence of particle size 
distribution and physicochemical characteristics, coupled with the beneficial effects of 
different biomaterials on biological and pharmacokinetic processes. 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Molecular structure of a. tigapotide (PCK 3145), b. QNPHOSEO-9 
polyelectrolyte block copolymer (the degrees of polymerization are m=162 and 
n=334) and c. PAMAM G-4 dendrimer. 
b. 
a. 
c. 
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Fig. 2. (a) Hydrodynamic Radius, Rh, (b) Polydispersity Index, (PD.I.), (c) ζ-
potential, (d) light scattering intensity at 90°, I, and (e) Rg/Rh as a function of 
CPCK3145, for the solutions of QNPHOSEO:PCK3145 system at pH=7.00 and 
0.01M NaCl (blue points) and at pH=7.40 and 0.154M NaCl (red points). 
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Fig. 3. (a) Hydrodynamic Radius, Rh and (b) ζ-potential, as a function of CPCK3145, for 
the solutions of QNPHOSEO:PCK3145 system at pH=7.00 and 0.01M NaCl (blue 
points) and at pH=7.40 and 0.154M NaCl (red points) at FBS. 
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Fig. 4. (a) Hydrodynamic Radius, Rh, (b) light scattering intensity at 90°, I, and (c) 
Rg/Rh, as a function of the added NaCl concentration of representative solutions, 
corresponding to low and high CPCK3145, of the QNPHOSEO:PCK3145 system at 
pH=7.00.  
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Fig. 5. (a) Hydrodynamic Radius, Rh, (b) light scattering intensity at 90°, I, and (c) 
Rg/Rh as a function of the added NaCl concentration of representative solutions, 
corresponding to low and high CPCK3145, of the QNPHOSEO:PCK3145 system at 
pH=7.40.  
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Fig. 6. Stability assessment of the liposomal nanoparticles: DPPC:PCK3145 (9:0.2 
molar ratio), EggPC:PCK (9:0.2 molar ratio), DPPC:SA:PCK3145 (9:1:0.2 molar 
ratio) and EggPC:SA:PCK3145 (9:1:0.2 molar ratio). 
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Scheme 1: The structure of dendritic nanoparticles complexing tigapotide. 
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